Swiss researchers studying the blood of people who lived past 100 have pinpointed 37 proteins that appear to distinguish centenarians from both younger healthy adults and older hospitalized patients, offering a molecular window into what separates extreme longevity from ordinary aging. The findings, published in the journal Aging Cell by investigators from the SWISS100 project, represent one of the most detailed proteomic comparisons of centenarian blood ever conducted. If validated in broader populations, these proteins could become targets for therapies designed to slow age-related decline.
How 723 Proteins Were Narrowed to 37
The SWISS100 team used a technology platform called PEA/Olink Explore to measure 723 circulating proteins in the plasma of centenarians living across Switzerland. They then compared those protein levels against two control groups: healthy adults aged 30 to 60 and hospitalized geriatric patients aged 80 to 90. The three-way comparison was designed to isolate proteins that were not simply elevated or suppressed by old age itself but that tracked specifically with exceptional survival, helping to separate signals of resilience from the background noise of typical aging.
Out of those 723 proteins, the researchers identified a distinct set of 37 youth-associated markers that were more abundant in centenarians than expected for their age. The label “youth-associated” reflects the fact that these proteins behaved in centenarian blood more like they do in the blood of people decades younger, suggesting that the centenarians’ biology had resisted some of the molecular deterioration that typically accompanies aging past 80. Together, they form a proteomic fingerprint that distinguishes those who reach 100 from both midlife adults and frail elders of similar chronological age.
Building on a Decade of Centenarian Blood Research
The SWISS100 results did not emerge in a vacuum. An earlier study, also published in Aging Cell, had already described a recurring protein signature in centenarians and their offspring, framing those proteomic patterns as biomarkers of slower biological aging. That earlier work argued that centenarians age more slowly than the general population at the molecular level, and that their children inherit some of that protection. The new Swiss data reinforces and extends that hypothesis by using a different cohort, a different country, and a more granular measurement platform, suggesting that certain longevity-linked proteins may be robust across families and environments.
Separately, research highlighted in a Nature news feature on centenarian blood showed that studying people who live past 100 can yield specific blood biomarkers tied to mortality risk. One example cited was neurofilament light chain, a protein already used in neurology as a marker of nerve damage that also predicts future cognitive decline and death. That precedent matters because it demonstrates that individual blood proteins identified in centenarian studies can have real clinical utility, not just academic interest. The question now is whether any of the 37 proteins from SWISS100 will prove similarly actionable for forecasting health span or guiding interventions.
Why Correlation Is Not Yet Causation
Finding a protein that is elevated in centenarians does not mean that boosting that protein in a younger person will extend their life. The SWISS100 study is observational: it captures association, not mechanism. The researchers measured what was present in centenarian blood, but they did not demonstrate that any single protein drove the longevity outcome. It is entirely possible that some youth-associated proteins are downstream reflections of healthier organs, lower inflammation, or favorable genetics rather than levers that can be pulled therapeutically. This distinction between marker and driver is a meaningful limitation that separates the current findings from a ready-made longevity treatment plan.
Other large-scale proteomic efforts face the same challenge. A separate longevity study published in Aging Cell used the Cardiovascular Health Study for discovery and AGES-Reykjavik for replication, building a protein-based prediction model with LASSO-selected markers. That work validated the idea that plasma protein signatures can predict who lives longer, but it also exposed how difficult replication across different populations can be, with some signals weakening or disappearing in the second cohort. The SWISS100 proteins have not yet been tested in non-Swiss populations, which means the 37-protein signature could look different in groups with distinct genetic backgrounds, diets, or healthcare systems, and some components may prove context-specific rather than universal hallmarks of slow aging.
Scaling Protein Discovery Beyond Small Cohorts
One reason proteomic aging research is accelerating is the growing infrastructure for measuring proteins at population scale. The UK Biobank proteomics initiative has built an industry consortium to measure plasma proteins across tens of thousands of participants, generating the kind of large datasets needed to test whether signatures like the SWISS100 panel hold up in diverse groups. With such resources, scientists can ask whether the same 37 proteins that distinguish Swiss centenarians also track with survival in people from the UK, other parts of Europe, and beyond, or whether new, population-specific markers emerge when sample sizes expand.
At the same time, public repositories indexed through the National Library of Medicine are making proteomic datasets increasingly accessible for independent verification and meta-analysis. Tools for tracking published findings, including personalized literature dashboards and curated bibliography collections, allow researchers to quickly locate and cross-reference centenarian studies from different countries and platforms. This growing digital ecosystem makes it easier to test whether a 37-protein signature is reproducible, to identify overlapping markers across studies, and to prioritize the most consistent candidates for deeper functional experiments in cells and animal models.
What These Proteins Mean for Aging Science
The practical value of the SWISS100 findings depends on what happens next. If even a handful of the 37 youth-associated proteins turn out to play a causal role in maintaining tissue integrity, dampening chronic inflammation, or preserving metabolic flexibility, they could become focal points for drug development or lifestyle interventions. For example, if a protein is found to protect against vascular damage, researchers could explore small molecules, antibodies, or gene-based therapies that modulate its pathway, while epidemiologists examine how diet, exercise, or environmental exposures influence its levels across the lifespan. Conversely, if most of the proteins prove to be passive readouts of underlying resilience, they may still be valuable as early warning systems that flag accelerated aging long before clinical disease appears.
In the nearer term, the 37-protein panel is likely to matter most as a research tool rather than a consumer test. By stratifying older adults according to how “centenarian-like” their proteomic profile appears, scientists can design more efficient trials of geroscience interventions, enriching studies with participants who are most or least biologically resilient. Such stratification could sharpen signals in trials of senolytics, exercise programs, or nutritional strategies aimed at extending health span, allowing smaller, shorter studies to detect meaningful changes. As more datasets accumulate and cross-cohort comparisons mature, the SWISS100 signature may evolve from a Swiss-specific curiosity into part of a broader, international framework for measuring biological age, and for understanding why a small fraction of people manage to stay remarkably young on the inside, even as they cross the threshold of 100 years.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
